CompanyTARSNasdaqIrvine, CA

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals develops treatments for eye care, dermatology, and infectious disease.

SEC EDGAR ClinicalTrials.gov xdemvy.com

8-KSep 14Latest SEC filing, period to Sep 14

Sep 10Latest story

September 2026

Tarsus files 8-K confirming closed terms of Alkeus acquisition and Stargardt drug rights

Sep 10Regulatory decisionTarsus Pharmaceuticals, Inc.

August 2026

Tarsus Pharmaceuticals prices $125 million private placement financing

Aug 6FinancingTarsus Pharmaceuticals, Inc.

Tarsus posts record XDEMVY sales, raises guidance, moves to acquire Alkeus

Aug 6Quarterly updatelotilaner ophthalmic solution Tarsus Pharmaceuticals, Inc.

July 2026

Tarsus Pharmaceuticals' chief commercial officer to depart July 15

Jul 13PeopleTarsus Pharmaceuticals, Inc.

Tarsus acquires iRenix Medical for up to $565 million to add late-stage eye drug IRX-101

Jul 8Clinical readoutTarsus Pharmaceuticals, Inc.